Global Myasthenia Gravis Treatment Market: Forecast and Trends
Report Scope:
This report aims to study the myasthenia gravis treatment global market size comprehensively. Current and historical market revenues can be estimated based on the product type, treatment by drug and region.
Report Includes:
54 data tables and 47 additional tables
An overview and analysis of the global market for myasthenia gravis (MG) treatments
Analyses of market trends, with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
Estimates of the market size, revenue forecasts and potential growth share analysis for MG treatments based on product, type, treatment modality, and region
In-depth information (facts and figures) pertaining to the major factors influencing the market (drivers, restraints, opportunities and challenges)
Analysis of the market growth opportunities through Porter’s Five Forces and PESTLE analyses, taking into consideration the prevailing microand macro environmental factors
An examination of the importance of ESG in the myasthenia gravis market, taking into account consumer attitudes, risks and opportunities, and the ESG practices of pharmaceutical and biotech companies
Discussion of the factors driving the market, industry trends and new developments
Analysis of relevant patents
Identification of the leaders in the field of MG
Profiles of the leading market players, including Profiles of the leading market players, including AbbVie, Bausch Health, Gilead Sciences, Merck & Co. Inc., Servier, and Teva
- Chapter 1 Introduction
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Methodology
- Information Sources
- Primary Research
- Secondary Research
- Geographic Breakdown
- Segmentation Breakdown
- Chapter 2 Summary and Highlights
- Market Outlook
- Report Highlights
- Chapter 3 Market Overview
- Myasthenia Gravis
- Ocular Myasthenia Gravis
- Generalized Myasthenia Gravis
- Transient Neonatal Myasthenia Gravis
- Global Regulatory Structure for Myasthenia Gravis
- Drug Approvals and Regulation
- Clinical Trials
- Patient Access and Health Insurance
- Pharmaceutical Pricing and Reimbursement
- Clinical Practice Guidelines
- Rare Disease Designation
- Patient Advocacy and Support
- Pricing and Reimbursement for the Treatment of Myasthenia Gravis
- North America
- Europe
- Asia-Pacific
- Therapies/Drugs Used to Treat Myasthenia Gravis
- Medications
- Surgery
- Intravenous (IV) Therapy
- Medications
- Chapter 4 Market Dynamics
- Market Drivers
- Growing Elderly Population
- Increasing Incidence and Prevalence
- Advancements in Myasthenia Gravis Diagnostics
- Research and Development
- Regulatory Environment
- Personalized Medicine
- Market Opportunities
- Unmet Medical Needs
- Advancements in Research and Development
- Biologics and Immunotherapies
- Global Expansion
- Increased Awareness
- Tailored Treatment Approaches
- Healthcare Reimbursement
- Patient-Centric Care
- Competitive Landscape
- Chronic Nature of Myasthenia Gravis
- Research Collaboration
- Market Restraints
- Limited Patient Population
- Diagnostic Challenges
- Lack of Disease-Modifying Therapies
- Reimbursement Issues
- Risks of Emerging Therapies
- Other Restraints
- Chapter 5 Market Breakdown by Region
- Market Overview
- North America
- Europe
- Asia-Pacific
- Chapter 6 Market Breakdown by Type
- Market Overview
- Generalized Myasthenia Gravis
- Transient Neonatal Myasthenia Gravis
- Ocular Myasthenia Gravis
- Chapter 7 Market Breakdown by Treatment Modality
- Introduction
- Medications
- Surgery
- Intravenous Therapy
- Chapter 8 Market Breakdown by Type of Product
- Monoclonal Antibodies
- Brands
- Cholinesterase Inhibitors
- Brand
- Intravenous Immunoglobulins
- Brands
- Immunosuppressants
- Brand
- Corticosteroids
- Brand
- Chapter 9 ESG Development
- Introduction
- Environment
- Social
- Governance
- Case Study
- AstraZeneca
- Concluding Remarks from BCC Research
- Chapter 10 Emerging Technologies and Developments
- Introduction
- Chapter 11 Competitive Intelligence
- Overview
- Industry Scenario
- Company Shares
- Chapter 12 Patent Analysis
- Patent Analysis by Manufacturer
- Chapter 13 Pipeline Analysis
- Clinical Trials
- Chapter 14 M&A and Venture Funding Outlook
- Introduction
- Chapter 15 Company Profiles
- ABBVIE
- AMYASTHENIA GRAVISEN INC.
- ASTELLAS PHARMA INC.
- ASTRAZENECA
- BAUSCH HEALTH COMPANIES INC.
- BAYER AG
- BIOGEN
- BRISTOL-MYERS SQUIBB
- CSL
- DAIICHI SANKYO CO. LTD.
- F. HOFFMANN-LA ROCHE AG
- GILEAD SCIENCES INC.
- GLAXOSMITHKLINE PLC.
- MERCK & CO. INC.
- NOVARTIS
- PFIZER INC.
- SANOFI
- SERVIER LABORATORIES
- TEVA PHARMACEUTICAL INDUSTRIES LTD.
- Chapter 16 Appendix: Acronyms
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook